JHS SVENDGAARD LABORATORIES LTD.

JHS Svendgaard Laboratories Ltd has issued a notice regarding its 22nd Annual General Meeting (AGM) scheduled for September 26, 2026. The AGM will be conducted via Video Conferencing. The company is providing shareholders, whose email IDs are not registered, with web links and QR codes to access the Annual Report for FY 2025-26 and the Notice of the 22nd AGM. Key details for e-voting are also provided, with the cut-off date for entitlement being September 19, 2026. The notice also serves as a reminder for KYC updation and dematerialization of physical securities, referencing recent SEBI circulars.

JHS Svendgaard Laboratories Ltd has announced its 22nd Annual General Meeting (AGM) will be held on September 26, 2026, at 3:00 PM IST. The meeting will be conducted through Video Conferencing (VC) / Other Audio-Visual Means (OAVM). Key agenda items include the adoption of audited standalone and consolidated financial statements for the fiscal year ended March 31, 2026, and the re-appointment of Mr. Paramvir Singh as a director liable to retire by rotation. The notice is being sent electronically to members, and the AGM notice is available on the company's website. The cut-off date for e-voting is September 19, 2026, with remote e-voting open from September 23 to September 25, 2026.

JHS Svendgaard Laboratories Ltd has filed its Annual Report for the Financial Year 2025-26, detailing its performance and strategic outlook. The company reported Revenue from Operations of ₹101.69 Crores for FY 2025-26. The report highlights a strong focus on manufacturing capabilities, innovation, and customer relationships within the FMCG and personal care sectors. The company is committed to investing in people, technology, and infrastructure to build a future-ready organization and aims to strengthen its core business, drive innovation, and expand its product portfolio for sustainable long-term value creation. The Annual Report also includes the Notice of the 22nd Annual General Meeting (AGM), which will be sent electronically to members.

JHS Svendgaard Laboratories Ltd has filed its Statement of Deviation and Variation for the quarter ended June 30, 2026, concerning funds raised via Preferential Issue. The company reported no deviation or variation in the utilization of funds. The funds were raised on June 4, 2024, amounting to ₹29.99 crores. The utilization details for setting up a new project in Jammu & Kashmir, general corporate purposes, and infusion of funds into a group entity (JHS Svendgaard Retail Ventures Ltd.) show that the utilized amounts align with the original allocations, with no discrepancies noted for the reported quarter. The information is available on the company's website.

JHS Svendgaard Laboratories Ltd announced that its Board of Directors has approved the Un-audited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. The results were reviewed by V.K. Khosla & Co., Chartered Accountants, who provided a Limited Review Report. The board meeting took place on August 11, 2026. The financial information will be available on the company's website.

JHS Svendgaard Laboratories Ltd announced that its Board of Directors, in a meeting held on August 11, 2026, considered and approved the un-audited standalone and consolidated financial results for the quarter ended June 30, 2026 (Q1 FY27). The limited review reports from the statutory auditors, V.K. Khosla & Co., were also enclosed. The board meeting commenced at 2:30 PM and concluded at 3:35 PM. The financial results will be made available on the company's website.

JHS Svendgaard Laboratories Ltd has announced that its Board of Directors will convene on August 11, 2026. The primary agenda item is to consider and approve the Un-Audited Financial Results, both standalone and consolidated, for the quarter ended June 30, 2026. Concurrently, the company has closed its trading window from July 1, 2026, which will remain shut for 48 hours post the announcement of these financial results, in compliance with SEBI regulations regarding insider trading.

JHS Svendgaard Laboratories Ltd has announced the closure of its trading window for the quarter ended June 30, 2026. This measure, in compliance with SEBI regulations and the company's insider trading code, restricts dealings in the company's securities by insiders and designated persons. The window will reopen 48 hours after the declaration of the unaudited financial results for the said quarter. The specific date of the board meeting to consider these results will be communicated later.

JHS Svendgaard Laboratories Ltd has filed a statement of deviation for the quarter ended March 31, 2026, regarding the utilization of funds raised through a preferential issue. The Board of Directors approved this statement on May 26, 2026. According to the filing, there was no deviation or variation in the use of funds raised. The funds were raised on June 4, 2024, amounting to ₹29.99 crores.

JHS Svendgaard Laboratories Ltd announced audited financial results for the quarter and year ended March 31, 2026. The Board of Directors approved the results in a meeting held on May 26, 2026, after review and recommendation by the Audit Committee. The auditor, V.K. Khosla & Co., issued an unmodified opinion on the standalone and consolidated financial results. The board meeting commenced at 3:40 P.M. and concluded at 4:30 P.M. Details are available on the company website.